{"DataElement":{"publicId":"5810389","version":"1","preferredName":"Intrathecal Therapeutic Procedure Administered Type","preferredDefinition":"A description of the intrathecal therapy that was administered.","longName":"2763950v1.0:2960386v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2763950","version":"1","preferredName":"Intrathecal Route of Administration Therapeutic Procedure Administered","preferredDefinition":"Administration of drugs directly into spinal subarachnoid space in the cerebrospinal fluid, at any level of the cerebrospinal axis, including injection into the cerebral ventricles, in order to bypass the blood-brain barrier and achieve local, rapid effects on the meninges or cerebrospinal axis._An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process._The act of having given something (e.g., a medication or test).","longName":"INT_ADM_TP_ADM","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2763948","version":"1","preferredName":"Intrathecal Route of Administration Therapeutic Procedure","preferredDefinition":"Administration within the cerebrospinal fluid at any level of the cerebrospinal axis, including injection into the cerebral ventricles.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C38267:C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intrathecal Route of Administration","conceptCode":"C38267","definition":"Administration of drugs directly into spinal subarachnoid space in the cerebrospinal fluid, at any level of the cerebrospinal axis, including injection into the cerebral ventricles, in order to bypass the blood-brain barrier and achieve local, rapid effects on the meninges or cerebrospinal axis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5196CE42-930A-69B2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-07-09","endDate":null,"createdBy":"STURGILLJ","dateCreated":"2008-07-09","modifiedBy":"ONEDATA","dateModified":"2008-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5196CE42-9318-69B2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-07-09","endDate":null,"createdBy":"STURGILLJ","dateCreated":"2008-07-09","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2960386","version":"1","preferredName":"Intrathecal Chemotherapy Type","preferredDefinition":"(in-tra-THEE-kal KEE-mo-THER-a-pee) Anticancer drugs that are injected into the fluid-filled space between the thin layers of tissue that cover the brain and spinal cord._Type; a subdivision of a particular kind of thing.","longName":"2960386v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Cytarabine","valueDescription":"Cytarabine (Ara C, Cytosine Arabinoside)","ValueMeaning":{"publicId":"2960387","version":"1","preferredName":"Cytarabine (Ara C, Cytosine Arabinoside)","longName":"2960387","preferredDefinition":"An anticancer drug that belongs to the family of drugs called antimetabolites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytarabine","conceptCode":"C408","definition":"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"780B7F9B-CE25-2E47-E040-BB89AD431007","latestVersionIndicator":"Yes","beginDate":"2009-11-10","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"780B7F9B-CE3E-2E47-E040-BB89AD431007","beginDate":"2009-11-10","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-10","modifiedBy":"ONEDATA","dateModified":"2009-11-10","deletedIndicator":"No"},{"value":"Methotrexate","valueDescription":"Methotrexate","ValueMeaning":{"publicId":"2567426","version":"1","preferredName":"Methotrexate","longName":"2567426","preferredDefinition":"An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methotrexate","conceptCode":"C642","definition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D46F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"CLOHNES","dateModified":"2022-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"780B7F9B-CE48-2E47-E040-BB89AD431007","beginDate":"2009-11-10","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-10","modifiedBy":"ONEDATA","dateModified":"2009-11-10","deletedIndicator":"No"},{"value":"Thiotepa","valueDescription":"Thiotepa","ValueMeaning":{"publicId":"2739553","version":"1","preferredName":"Thiotepa","longName":"2739553","preferredDefinition":"A synthetic alkylating agent. Related to nitrogen mustard, thiotepa alkylates and crosslinks DNA, resulting in the inhibition of DNA replication. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thiotepa","conceptCode":"C875","definition":"A polyfunctional, organophosphorus alkylating agent and a stable derivative of N,N',N''-triethylenephosphoramide (TEPA), with antineoplastic activity. Upon administration, thiotepa is converted into highly reactive ethylenimine groups, which covalently bind to nucleophilic groups in DNA and demonstrate a preference for the N7 position of guanine bases. This induces crosslinking of alkylated guanine bases in double-stranded DNA, interferes with both DNA replication and cell division, and results in both the induction of apoptosis and the inhibition of cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A7528ED-0294-5EF5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"780B7F9B-CE52-2E47-E040-BB89AD431007","beginDate":"2009-11-10","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-10","modifiedBy":"ONEDATA","dateModified":"2009-11-10","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other Intrathecal Chemotherapy","ValueMeaning":{"publicId":"3028643","version":"1","preferredName":"Other Intrathecal Chemotherapy","longName":"3028643","preferredDefinition":"Different than the one(s) previously specified or mentioned.: (in-tra-THEE-kal KEE-mo-THER-a-pee) Anticancer drugs that are injected into the fluid-filled space between the thin layers of tissue that cover the brain and spinal cord.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Intrathecal Chemotherapy","conceptCode":"C15750","definition":"Chemotherapy delivered via the spinal canal.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8253A0BB-BB70-CBD2-E040-BB89AD4349C1","latestVersionIndicator":"Yes","beginDate":"2010-03-21","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-03-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8253A0BB-BB88-CBD2-E040-BB89AD4349C1","beginDate":"2009-11-10","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-03-21","modifiedBy":"ONEDATA","dateModified":"2010-03-21","deletedIndicator":"No"},{"value":"Hydrocortisone","valueDescription":"Therapeutic Hydrocortisone","ValueMeaning":{"publicId":"2578183","version":"1","preferredName":"Therapeutic Hydrocortisone","longName":"2578183","preferredDefinition":"A synthetic or semisynthetic analog of natural hydrocortisone hormone produced by the adrenal glands with primary glucocorticoid and minor mineralocorticoid effects. As a glucocorticoid receptor agonist, hydrocortisone promotes protein catabolism, gluconeogenesis, capillary wall stability, renal excretion of calcium, and suppresses immune and inflammatory responses. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Hydrocortisone","conceptCode":"C555","definition":"A synthetic or semisynthetic analog of natural hydrocortisone hormone produced by the adrenal glands with primary glucocorticoid and minor mineralocorticoid effects. As a glucocorticoid receptor agonist, hydrocortisone promotes protein catabolism, gluconeogenesis, capillary wall stability, renal excretion of calcium, and suppresses immune and inflammatory responses. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE74-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"99D69ED0-6BFF-546F-E053-F662850A1DAA","beginDate":"2019-12-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2960385","version":"1","preferredName":"Intrathecal Chemotherapy Type","preferredDefinition":"(in-tra-THEE-kal KEE-mo-THER-a-pee) Anticancer drugs that are injected into the fluid-filled space between the thin layers of tissue that cover the brain and spinal cord.:Type; a subdivision of a particular kind of thing.","longName":"C15750:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intrathecal Chemotherapy","conceptCode":"C15750","definition":"Chemotherapy delivered via the spinal canal.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"780B7F9B-CE00-2E47-E040-BB89AD431007","latestVersionIndicator":"Yes","beginDate":"2009-11-10","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-10","modifiedBy":"ONEDATA","dateModified":"2009-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"780B7F9B-CE11-2E47-E040-BB89AD431007","latestVersionIndicator":"Yes","beginDate":"2009-11-10","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-10","modifiedBy":"KUMMEROA","dateModified":"2019-12-16","changeDescription":". PVs added for 2018. AK 8/21/17 PV added for another context. AK 2019-12-16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685478","version":"1","longName":"Testing Set – Moderately Different","context":"NCIP"}]}],"AlternateNames":[{"name":"PerformedSubstanceAdministration:value","type":"HCT_BRIDG_5","context":"NHLBI"},{"name":"COG","type":"USED_BY","context":"COG"},{"name":"ITT_TX","type":"COG GDE Short Name","context":"COG"}],"ReferenceDocuments":[{"name":"What was the type of intrathecal therapy administered?","type":"Alternate Question Text","description":"What was the type of intrathecal therapy administered?","url":null,"context":"NHLBI"},{"name":"What was the intrathecal ther","type":"Preferred Question Text","description":"What was the intrathecal therapy that was administered?","url":null,"context":"NHLBI"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Intrathecal therapy given:","url":null,"context":"COG"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4EF48B13-E843-3E8A-E053-F662850A996E","latestVersionIndicator":"Yes","beginDate":"2017-05-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-07","modifiedBy":"LEEW","dateModified":"2020-01-07","changeDescription":"System generated def displayed as alt def. released 8/28/17; Added HCT_BRIDG5 alternate name - RR 2018-12-23","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}